logo
Share SHARE
FONT-SIZE Plus   Neg

Bayer: Late Stage Study Of Regorafenib Meets Primary Goal In Tumor Patients

Bayer AG's (BYR.L,BAYRY.PK,BAYZF.PK) Bayer HealthCare on Tuesday announced positive results from its Phase III trial GRID evaluating its investigational compound regorafenib for the treatment of patients with metastatic and/or unresectable gastrointestinal stromal tumors, or GIST, whose disease has progressed despite prior treatment with imatinib and sunitinib.

The trial met its primary endpoint of statistically significantly improving progression-free survival. The safety and tolerability of regorafenib were generally as expected in the study. Detailed data from the study are expected to be presented at an upcoming scientific meeting.

Kemal Malik, Head of Global Development and member of the Bayer HealthCare Executive Committee, said, "Additional treatment options are needed for GIST patients after failure of approved drugs. These findings may represent important progress in this difficult-to-treat disease with high unmet patient need."

Bayer plans to submit regorafenib for marketing authorization in the treatment of metastatic and/or unresectable GIST based on these data.

Regorafenib has also shown positive results in a Phase III trial for the treatment of patients with metastatic colorectal cancer whose disease has progressed after approved standard therapies. Bayer plans to submit regorafenib for marketing authorization in this indication in the first half of 2012.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
TCL Communications CEO Nicolas Zibell announced the plan to launch new Blackberry brand smartphone with superior security features. The new android phone BlackBerry KeyOne will be a beginning of a new story, he noted. Though the iPhones with smarter and popular features killed the Canadian smartphone maker, the BlackBerry brand has been maintaining strong fan-following around the globe. Its secu In response to stiff competition from its rivals, AT&T Inc. has lowered the price of its unlimited data plan and is also offering a video credit if customers subscribe to a video service plan. The unlimited mobile data plan was made available to all AT&T customers less than two weeks ago. The plan for a single phone will now cost $90 for the first line, a price cut of $10. Discount-store operator Target, Inc. on Tuesday reported a 43 percent decline in profit in the fourth quarter from last year, reflecting lower sales and weaker margins. In addition, the prior-year period's results included a one-time gain. Adjusted earnings per share for the latest quarter missed analysts' expectations.
comments powered by Disqus
Follow RTT